<DOC>
	<DOCNO>NCT01859858</DOCNO>
	<brief_summary>Curcumin extract tumeric root show anti-tumor property laboratory study . Curcumin , parent spice , turmeric ( curcuma longa ) , 4th commonly purchase dietary supplement U.S . Many cancer patient take curcumin treatment cancer purport health benefit . This research study design learn safety , pharmacokinetics effectiveness irinotecan give combination curcumin patient metastatic colorectal cancer . The study body absorbs , process eliminates drug call pharmacokinetics ( PK ) . One main purpose study good understand interaction curcumin irinotecan measuring level irinotecan blood ( ie . measure irinotecan PK ) patient also take curcumin . Information collect study could result improved dosing guideline lead effective treatment cancer less toxicity .</brief_summary>
	<brief_title>Effect Curcumin Dose Limiting Toxicity Pharmacokinetics Irinotecan Patients With Solid Tumors</brief_title>
	<detailed_description>Treatment Plan This single-center , two-part , open label prospective study define maximum tolerate dose ( MTD ) curcumin plus irinotecan pharmacokinetic effect curcumin irinotecan metabolism patient advanced colorectal cancer . Each cycle irinotecan define 28 day , dose irinotecan administer D1 D15 . The study two part : Part 1 comprises dose escalation portion study Part 2 comprises MTD expansion pharmacokinetic study . Patients recruit GI oncology clinic North Carolina Cancer Hospital . After obtain informed consent , patient enter Part 1 study MTD define . During study Part 1 , patient give 4 day run-in curcumin prior irinotecan dosing . The plan dose level curcumin 1 , 2 , 3 , 4 gram per day . Irinotecan dose 200 mg/m2 IV day 1 15.46 Additional antineoplastic agent allow trial . Two patient enrol dose level DLT occur , begin low dose level increase level 2 patient successfully complete full irinotecan cycle dose level . Part 2 investigate effect curcumin irinotecan SN-38 pharmacokinetics . We expand cohort patient define MTD part 1 . Patients receive irinotecan alone single dose ( D1 ) . Curcumin , MTD , start D11 continue end cycle ( D28 ) . Irinotecan administer D15 . Blood sample collect day irinotecan infusion ( D1 D15 ) follow : prior treatment irinotecan ( baseline ) , immediately follow end irinotecan infusion , 0.5 , 1 , 1.5 , 2 , 4 , 6 , 24 hour follow end irinotecan infusion irinotecan SN-38 PK . All patient continue curcumin + irinotecan cycle disease progression toxicity occur discretion treat physician ( see section 5.6 ) . For patient study Part 1 , offer escalate curcumin dose high dose level safely complete MTD estimate . Treatment Assignment Part 1 : At end screening period , eligible patient assign cohort 2 escalate dos first Dose Limiting Toxicity ( DLT ) observe . DLT determination make base one cycle initial cohort 2 . As much information possible use initial cohort 2 . After first DLT observe , DLT rate dose estimate use isotonic regression . For , proportion DLTs compute dose first , , violation monotonicity , data violate dose level pool new proportion compute . The estimated DLT rate current dose use determine whether dose increase , decrease remain unchanged . The dose remain unchanged estimate DLT rate current dose [ 0.17 , 0.33 ] ; dose decrease estimated DLT rate high 0.33 ; dose increase estimate DLT low 0.17 . Dose assignment progress successful completion two participant dose level DLT occur . Dose assignment first DLT make collaboration study statistician patient . For Part 1 , 20 patient assign use algorithm . The MTD estimate either high dose reach DLTs 20 patient complete algorithm . Part 2 : After MTD estimate , 10 new patient assign `` expanded MTD cohort '' estimate PK parameter irinotecan SN-38 ( active metabolite irinotecan ) without curcumin . . The `` expand MTD cohort '' might 10 patient Part 1 sample size small 20 , long total number patient trial exceed 30 . The estimate MTD might re-evaluated estimate DLT rate dose outside [ 0.17 , 0.33 ] .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Curcumin</mesh_term>
	<criteria>Inclusion Criteria 1 . Age ≥21 year age ( upper age limit ) 2 . Histological cytological documentation metastatic adenocarcinoma colon rectum . Biopsy primary tumor alone adequate patient clear evidence metastatic disease and/or elevate Carcinoembryonic antigen ( CEA ) treat physician feel biopsy metastatic disease clinically warrant . 3 . Prior therapy oxaliplatin fluoropyrimidine require . One prior line therapy irinotecan allow . Prior therapy antiEpidermal Growth Factor Receptor ( EGFR ) agent also allow . 4 . Life expectancy least 3 month opinion treat investigator 5 . Eastern Cooperative Oncology Group performance status ≤1 ( Appendix B ) 6 . Adequate bone marrow , renal , hepatic function , evidence follow within 7 day treatment initiation curcumin : absolute neutrophil count ( ANC ) ≥1,500/mm3 platelet ≥100,000/mm3 hemoglobin ≥9.0 g/dL serum creatinine ≤1.5 x upper limit normal ( ULN ) aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) ≤ 3 x ULN Total bilirubin ≤ 1.5 x ULN 7 . Women childbearing potential male subject must agree use adequate contraception duration study participation . Adequate contraception define medically recommend method ( combination method ) per standard care . 8 . Medical oncologist agree four day window curcumin alone appropriate/safe prior start irinotecan trial candidate . 9 . The subject capable understanding comply parameter outline protocol 10 . Signed , Institutional Review Board ( IRB ) approve write informed consent 1 . Any prior allergy curcumin turmeric . 2 . Prior intolerance irinotecan necessity dose reduction great 20 % 3 . Patients already know homozygous UGT1A1*28 allele ( UDPglucuronosyltransferase 11*28 ) , patient Asian descent homozygous heterozygous UGT1A1*6 allele exclude due altered irinotecan metabolism 4 . Pregnant breastfeeding patient . Women childbearing potential must document negative pregnancy test maximum 7 day start treatment . 5 . History Gilbert 's syndrome 6 . Active cardiac disease include follow : Congestive heart failure ≥Class 2 accord New York Heart Association [ NYHA ] ( see Appendix C ) Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . Myocardial infarction le 6 month start Day 1 irinotecan . Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) 7 . Ongoing infection &gt; Grade 2 accord NCI Common Terminology Criteria Adverse Events version 4.0 ( CTCAE v. 4.0 ) 8 . Known history human immunodeficiency virus ( HIV ) infection 9 . Symptomatic metastatic brain meningeal tumor unless patient &gt; 3 month definitive therapy , negative imaging study within 4 week irinotecan initiation , clinically stable respect tumor time study entry . Also , patient must undergo acute steroid therapy taper ( chronic steroid therapy acceptable provide dose stable one month prior D1 treatment study ) 10 . Inability swallow oral medication malabsorption condition 11 . Patients diarrhea CTCAE v4 grade ≥2 12 . Unresolved toxicity high CTCAE v. 4.0 Grade 1 attribute prior therapy/procedure exclude alopecia oxaliplatininduced neurotoxicity ( must ≤ Grade 2 ) 13 . Substance abuse , medical , psychological , social condition may interfere patient 's participation study evaluation study result 14 . Patients unwilling unable refrain use moderate strong inhibitor inducer Cytochrome P450 , family 3 , subfamily A ( CYP3A ) ( Appendix A )</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mCRC ( metastatic colorectal cancer )</keyword>
	<keyword>CRC ( colorectal cancer )</keyword>
	<keyword>Advanced colorectal cancer</keyword>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Colon cancer</keyword>
</DOC>